Unknown PHASE4 INTERVENTIONAL 2-arm NCT03208998

The Changes of Natural Killer Cells Frequency and Function During Antiviral Therapy

The Changes of Natural Killer Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B.

Sponsor: Beijing Ditan Hospital

Conditions Chronic Hepatitis B Infection

Interventions Peginterferon Alfa-2a

Updated 6 times since 2017 Last updated: Jul 10, 2017 Started: Jan 31, 2016 Primary completion: Dec 31, 2017 Completion: Dec 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Chronic Hepatitis B Infection and is currently ongoing. Beijing Ditan Hospital leads this study, which shows 6 recorded versions since 2016 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Aug 2019 — Jan 2021 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status
Jun 2018 — Aug 2019 [monthly]

Recruiting PHASE4

▶ Show 1 earlier version

Aug 2017 — Jun 2018 [monthly]

Recruiting PHASE4

First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Ditan Hospital

Data source: Beijing Ditan Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China